HOXB5 overexpression is associated with neuroendocrine differentiation and poor prognosis in prostate cancer

Supplementary Table 1 Clinicopathologic characteristics of 128 PCa patients who were treated with radical prostatectomy.

Supplementary Table 2 Clinicopathologic characteristics of 74 with metastatic PCa with androgen deprivation therapy

Supplementary figure 1 The expression of HOXB5 from GSE147250 (A) HOXB5 expression in control, RB1 knockout, TP53 knockout, and double (RB1/TP53) knockout cells in LNCaP. KO: knockout, DKO: double knockout (B) HOXB5 expression in control, and double (RB1/TP53) knockout cells in LNCaP treated with enzalutamide. DKO: double knockout